Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study
Authors:
- Marloes J HuijbersMHMarloes J Huijbers
- Jan SpijkerJSJan Spijker
- A Rogier T DondersADA Rogier T Donders
- Digna Jf van SchaikDSDigna Jf van Schaik
- Patricia van OppenPOPatricia van Oppen
- Henricus G RuhéHRHenricus G Ruhé
- Marc B J BlomMBMarc B J Blom
- Willem A NolenWNWillem A Nolen
- Johan OrmelJOJohan Ormel
- Gert Jan van der WiltGWGert Jan van der Wilt
- Willem KuykenWKWillem Kuyken
- Philip SpinhovenPSPhilip Spinhoven
Open Access
- 27 August 2012
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 12 (1) , 1-11
Abstract
Depression is a common psychiatric disorder characterized by a high rate of relapse and recurrence. The most commonly used strategy to prevent relapse/recurrence is maintenance treatment with antidepressant medication (mADM). Recently, it has been shown that Mindfulness-Based Cognitive Therapy (MBCT) is at least as effective as mADM in reducing the relapse/recurrence risk. However, it is not yet known whether combination treatment of MBCT and mADM is more effective than either of these treatments alone. Given the fact that most patients have a preference for either mADM or for MBCT, the aim of the present study is to answer the following questions. First, what is the effectiveness of MBCT in addition to mADM? Second, how large is the risk of relapse/recurrence in patients withdrawing from mADM after participating in MBCT, compared to those who continue to use mADM after MBCT? Two parallel-group, multi-center randomized controlled trials are conducted. Adult patients with a history of depression (3 or more episodes), currently either in full or partial remission and currently treated with mADM (6 months or longer) are recruited. In the first trial, we compare mADM on its own with mADM plus MBCT. In the second trial, we compare MBCT on its own, including tapering of mADM, with mADM plus MBCT. Follow-up assessments are administered at 3-month intervals for 15 months. Primary outcome is relapse/recurrence. Secondary outcomes are time to, duration and severity of relapse/recurrence, quality of life, personality, several process variables, and incremental cost-effectiveness ratio. Taking into account patient preferences, this study will provide information about a) the clinical and cost-effectiveness of mADM only compared with mADM plus MBCT, in patients with a preference for mADM, and b) the clinical and cost-effectiveness of withdrawing from mADM after MBCT, compared with mADM plus MBCT, in patients with a preference for MBCT. ClinicalTrials.gov: NCT00928980Keywords
This publication has 50 references indexed in Scilit:
- Competence in Teaching Mindfulness-Based Courses: Concepts, Development and AssessmentMindfulness, 2011
- Antidepressant Monotherapy vs Sequential Pharmacotherapy and Mindfulness-Based Cognitive Therapy, or Placebo, for Relapse Prophylaxis in Recurrent DepressionArchives of General Psychiatry, 2010
- How does mindfulness-based cognitive therapy work?Behaviour Research and Therapy, 2010
- Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression.Journal of Consulting and Clinical Psychology, 2008
- The Development and Validation of a Scale to Measure Self-CompassionSelf and Identity, 2003
- Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.Journal of Consulting and Clinical Psychology, 2000
- The role of rumination in depressive disorders and mixed anxiety/depressive symptoms.Journal of Abnormal Psychology, 2000
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986